Motley Fool Stock Advisor

Analysts see Regeneron as a high-quality, founder-led biotech with 10–15% total-return potential over five years. Durable franchises and a strong balance sheet offset patent and biosimilar risks that investors should monitor. - Business strength: Dupixent and Eylea are core franchises but face immunology competition and biosimilar pressure. - Management: Founder-led leadership praised for R&D and execution; succession planning remains an open question. - Financials: Low debt, roughly $8B cash/short-term plus ~$10B long-term investments; active buybacks and a new dividend. - Valuation and returns: Analysts forecast about 10–15% total returns over five years, with pipeline catalysts as upside drivers. - Key risks and monitors: Dupixent patent timeline (~2031), Eylea biosimilars, clinical/regulatory execution, and late-stage readouts such as Libtayo + fianlimab. ------------------------------------------------------------------------ This video is brought to you by The Motley Fool. Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 884% as of 3/30/2026 and measured against the S&P 500 returns of 179% as of 3/30/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well. ------------------------------------------------------------------------